Scalper1 News
Biotech Alnylam Pharmaceuticals (ALNY) reported positive data Friday on a rare-disease drug candidate and potential competitor to Alexion’s (ALXN) blockbuster Soliris. The market was underwhelmed, however, and Alnylam stock was down more than 3% in midday trading. Alnylam reported initial results from a phase 1/2 trial of ALN-CC5, a drug it’s developing with Sanofi’s (SNY) Genzyme division that targets complement component C5. Complements are Scalper1 News
Scalper1 News